- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Dr Robert Gabbay Discusses Disseminating the Joslin Clinical Guidelines
The Joslin Clinical Guidelines are designed to be streamlined and disseminated as widely as possible, explained Robert A. Gabbay, MD, PhD, FACP, senior vice president and chief medical officer of Joslin Diabetes Center.
The Joslin Clinical Guidelines are designed to be streamlined and disseminated as widely as possible, explained Robert A. Gabbay, MD, PhD, FACP, senior vice president and chief medical officer of Joslin Diabetes Center.
Transcript
How do you hope the Joslin Clinical Guidelines will be used to reach a wider audience?
We’re really interested in the potential impact of these guidelines to influence care, and they’ve been designed in a way where they’re really streamlined in terms of the length of them. Originally, as I mentioned, we had the Jocelyn textbook of diabetes. People, nowadays, sadly don’t have the time to read textbooks anymore, so this is really a condensed version of distillation of the evidence to say if you’re a healthcare provider, here’s the best evidence on how to manage your patients with diabetes. But also, if you’re a payer and you’re trying to ensure that the quality exists within your network, what should you be looking for in other healthcare providers to be adhering to the best evidence out there? So, we look to really disseminate this as widely as possibly, ultimately, to impact high quality care.
Inside the Center's MDD Value Model and Its Use of Dynamic Pricing
May 13th 2025Larragem Raines, MS, of the Center for Innovation & Value Research, discusses the organization's major depressive disorder (MDD) open-source value model, dynamic pricing, and the future role of artificial intelligence in care.
Listen
Real-World Data Show Bevacizumab Benefits Only High-Risk Patients With Epithelial Ovarian Cancer
May 13th 2025In line with previous clinical trial findings, real-world data show that bevacizumab improves outcomes in patients with epithelial ovarian cancer and high-risk prognostic factors.
Read More
For Patients Who Cannot Wait, This Off-the-Shelf CAR NK Treatment for AML Leaves Healthy Cells Alone
May 12th 2025First part of a 2-part interview with Stephen Strickland, MD, MSCI, director of leukemia research for Sarah Cannon Research Institute. Strickland recently presented data from a phase 1 trial of SENTI-202, an investigational chimeric antigen receptor (CAR) natural killer (NK) cell therapy.
Read More
